DR. REDDYS LAB has announced its results for the quarter ended June 2018. Here is a detailed performance review of the same:
No. of Mths Qtr. Ending | 3 Jun-17* | 3 Mar-18* | 3 Jun-18* | QoQ Change | YoY Change | |
---|---|---|---|---|---|---|
Net Sales | Rs m | 33,332 | 35,539 | 37,365 | 5.1% | 12.1% |
Other income | Rs m | 380 | 449 | 504 | 12.2% | 32.6% |
Turnover | Rs m | 33,712 | 35,988 | 37,869 | 5.2% | 12.3% |
Expenses | Rs m | 30,100 | 29,903 | 29,677 | -0.8% | -1.4% |
Gross profit | Rs m | 3,330 | 5,705 | 7,771 | 36.2% | 133.4% |
Depreciation | Rs m | 2,592 | 2,763 | 2,787 | 0.9% | 7.5% |
Interest | Rs m | 215 | 178 | 195 | 9.6% | -9.3% |
Profit before tax | Rs m | 903 | 3,213 | 5,293 | 64.7% | 486.2% |
Tax | Rs m | 237 | 492 | 532 | 8.1% | 124.5% |
Profit after tax | Rs m | 666 | 2,721 | 4,761 | 75.0% | 614.9% |
Gross profit margin | % | 10.0 | 16.1 | 20.8 | ||
Effective tax rate | % | 26.2 | 15.3 | 10.1 | ||
Net profit margin | % | 2.0 | 7.6 | 12.6 |
To see how DR. REDDYS LAB has performed over the last eight quarters, please visit here.
Over the last one year, DR. REDDYS LAB share price has moved up from Rs 2,621.5 to Rs 2,085.1, registering a Loss of Rs 536.4 or around 20.5%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,056.0 (up 0.7%). Over the last one year it has moved down from 14,668.6 to 14,056.0, a gain of 613 points (down 4.2%).
Overall, the S&P BSE SENSEX is up 0.8% over the year.
At the current price of Rs 2,085.1, the price to earnings (P/E) ratio of DR. REDDYS LAB stands at 25.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.7 times.
| |
For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsWhat to do after every trade.
What we can learn from one of the greatest traders to have ever lived.
This corner of the market could provide more returns than blue chips in 2020.
Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
2019 will be remembered as the year of great money-making IPOs...
More
| |
Equitymaster requests your view! Post a comment on "DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!